"
Team:SupBiotech-Paris/Acknowledgement
From 2009.igem.org
(Difference between revisions)
(→Our Sponsors) |
Enguerrand (Talk | contribs) |
||
| Line 8: | Line 8: | ||
==UMR CNRS 8121 from the Gustave Roussy Institute== | ==UMR CNRS 8121 from the Gustave Roussy Institute== | ||
| - | *Lluis M. Mir | + | :*Lluis M. Mir |
| - | *Karim Benihoud | + | :*Karim Benihoud |
==INSERM U872== | ==INSERM U872== | ||
| - | *Srinivas Kaveri | + | :*Srinivas Kaveri |
==AnyGenes== | ==AnyGenes== | ||
| - | *Benyoussef Naimi | + | :*Benyoussef Naimi |
==Our Sponsors== | ==Our Sponsors== | ||
| - | *Embassy of France in Washington [http://fr.ambafrance-us.org/spip.php?rubrique=[Link]] | + | :*Embassy of France in Washington [http://fr.ambafrance-us.org/spip.php?rubrique=[Link]] |
| - | *Eurogentec [http://www.eurogentec.com/eu-home.html [Link]] | + | :*Eurogentec [http://www.eurogentec.com/eu-home.html [Link]] |
| - | *Takara [http://www.takarabioeurope.com/ [Link]] | + | :*Takara [http://www.takarabioeurope.com/ [Link]] |
| - | *Clontech [http://www.clontech.com/ [Link]] | + | :*Clontech [http://www.clontech.com/ [Link]] |
| - | *Promega [http://www.promega.com/ [Link]] | + | :*Promega [http://www.promega.com/ [Link]] |
| - | *Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]] | + | :*Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]] |
| - | *Qiagen [http://www1.qiagen.com/ [Link]] | + | :*Qiagen [http://www1.qiagen.com/ [Link]] |
| - | *Fisher-Scientific [http://www.fr.fishersci.com/ [Link]] | + | :*Fisher-Scientific [http://www.fr.fishersci.com/ [Link]] |
|} | |} | ||
Revision as of 14:55, 23 August 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
Contents |
UMR CNRS 8121 from the Gustave Roussy Institute
- Lluis M. Mir
- Karim Benihoud
INSERM U872
- Srinivas Kaveri
AnyGenes
- Benyoussef Naimi
